These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 51285)

  • 41. Studies with bromocriptine. Part 1. "On-off" phenomena.
    Kartznel R; Calne DB
    Neurology; 1976 Jun; 26(6 PT 1):508-10. PubMed ID: 945489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study.
    LeWitt PA; Gopinathan G; Ward CD; Sanes JN; Dambrosia JM; Durso R; Calne DB
    Neurology; 1982 Jan; 32(1):69-72. PubMed ID: 7033825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
    Montastruc JL; Rascol O; Rascol A
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):773-5. PubMed ID: 2664089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
    Hutt CS; Snider SR; Fahn S
    Neurology; 1977 Jun; 27(6):503-10. PubMed ID: 577299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopaminergic agonists in Parkinsonism.
    Claveria LE; Teychenne PF; Calne DB; Petrie A; Bassendine MF
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096576
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
    Gilligan B; Wodak J; Stark R; O'Halloran M
    Med J Aust; 1979 Aug; 2(4):205-7. PubMed ID: 390336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of Parkinson's disease with pergolide: a double-blind study.
    Ahlskog JE; Muenter MD
    Mayo Clin Proc; 1988 Oct; 63(10):969-78. PubMed ID: 3050300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S79-82. PubMed ID: 12211145
    [No Abstract]   [Full Text] [Related]  

  • 54. Current status of dopamine agonists in Parkinson's disease management.
    Montastruc JL; Rascol O; Senard JM
    Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.